INTI (Inhibitor Therapeutics) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Inhibitor Therapeutics is: No Data: Cannot be evaluated.

Competitive Comparison of Inhibitor Therapeutics's Risk Assessment

For the Biotechnology subindustry, Inhibitor Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibitor Therapeutics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Inhibitor Therapeutics's Risk Assessment falls into.

Inhibitor Therapeutics (OTCPK:INTI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Inhibitor Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

4905 South West Shore Boulevard, Tampa, FL, USA, 33611-3329

Website

https://www.inhibitortx.com

Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Executives

Black Robe Capital Llc	10 percent owner	900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii	10 percent owner	1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman	director, 10 percent owner	1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii	10 percent owner	C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc	10 percent owner	12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez	director	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty	10 percent owner, officer: See Remarks	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara	officer: CFO and Treasurer	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie	director	4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin	director	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab	director, officer: Chairman of the Board	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606